Cushing's Disease: Sustained remission in five cases induced by medical therapy with the dopamine agonist cabergoline

Omayma ElShafie; Anjum Osman; Fatima Aamer; Ali Al-Mamari; N. J.Y. Woodhouse

doi:10.12816/0003176

Cushing's Disease: Sustained remission in five cases induced by medical therapy with the dopamine agonist cabergoline

Omayma ElShafie^*, Anjum Osman, Fatima Aamer, Ali Al-Mamari, N. J.Y. Woodhouse

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

We report five cases of Cushing's disease where the patients were given a therapeutic trial of cabergoline. Morning serum cortisol, adrenocorticotrophic hormone (ACTH), and sleeping cortisol concentrations were significantly raised. Magnetic resonance imaging (MRI) scans revealed pituitary microadenomas in 3 patients but were normal in the others. Ectopic ACTH production was excluded in the 2 patients with normal MRI scans. All were given a therapeutic trial of cabergoline (1 mg daily). Four patients responded with a prompt fall in serum cortisol levels and had a sustained clinical and biochemical remission for 378, 44, 28 and 14 days, respectively. One patient failed to respond. In conclusion, we suggest that all patients with Cushing's disease should undergo a therapeutic trial of cabergoline. Responders can then be prepared for surgery or, if needed, treated medically in the long term.

Original language	English
Pages (from-to)	493-497
Number of pages	5
Journal	Sultan Qaboos University Medical Journal
Volume	12
Issue number	4
DOIs	https://doi.org/10.12816/0003176
Publication status	Published - Nov 2012

Keywords

Adrenocorticotrophic hormone
Cabergoline
Case report
Cushing's disease
Dopamine receptors
Oman

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.12816/0003176

Cite this

@article{5980b198d74c4c40a71140da77d11ea8,

title = "Cushing's Disease: Sustained remission in five cases induced by medical therapy with the dopamine agonist cabergoline",

abstract = "We report five cases of Cushing's disease where the patients were given a therapeutic trial of cabergoline. Morning serum cortisol, adrenocorticotrophic hormone (ACTH), and sleeping cortisol concentrations were significantly raised. Magnetic resonance imaging (MRI) scans revealed pituitary microadenomas in 3 patients but were normal in the others. Ectopic ACTH production was excluded in the 2 patients with normal MRI scans. All were given a therapeutic trial of cabergoline (1 mg daily). Four patients responded with a prompt fall in serum cortisol levels and had a sustained clinical and biochemical remission for 378, 44, 28 and 14 days, respectively. One patient failed to respond. In conclusion, we suggest that all patients with Cushing's disease should undergo a therapeutic trial of cabergoline. Responders can then be prepared for surgery or, if needed, treated medically in the long term.",

keywords = "Adrenocorticotrophic hormone, Cabergoline, Case report, Cushing's disease, Dopamine receptors, Oman",

author = "Omayma ElShafie and Anjum Osman and Fatima Aamer and Ali Al-Mamari and Woodhouse, {N. J.Y.}",

year = "2012",

month = nov,

doi = "10.12816/0003176",

language = "English",

volume = "12",

pages = "493--497",

journal = "Sultan Qaboos University Medical Journal",

issn = "2075-051X",

publisher = "Sultan Qaboos University",

number = "4",

}

TY - JOUR

T1 - Cushing's Disease

T2 - Sustained remission in five cases induced by medical therapy with the dopamine agonist cabergoline

AU - ElShafie, Omayma

AU - Osman, Anjum

AU - Aamer, Fatima

AU - Al-Mamari, Ali

AU - Woodhouse, N. J.Y.

PY - 2012/11

Y1 - 2012/11

N2 - We report five cases of Cushing's disease where the patients were given a therapeutic trial of cabergoline. Morning serum cortisol, adrenocorticotrophic hormone (ACTH), and sleeping cortisol concentrations were significantly raised. Magnetic resonance imaging (MRI) scans revealed pituitary microadenomas in 3 patients but were normal in the others. Ectopic ACTH production was excluded in the 2 patients with normal MRI scans. All were given a therapeutic trial of cabergoline (1 mg daily). Four patients responded with a prompt fall in serum cortisol levels and had a sustained clinical and biochemical remission for 378, 44, 28 and 14 days, respectively. One patient failed to respond. In conclusion, we suggest that all patients with Cushing's disease should undergo a therapeutic trial of cabergoline. Responders can then be prepared for surgery or, if needed, treated medically in the long term.

AB - We report five cases of Cushing's disease where the patients were given a therapeutic trial of cabergoline. Morning serum cortisol, adrenocorticotrophic hormone (ACTH), and sleeping cortisol concentrations were significantly raised. Magnetic resonance imaging (MRI) scans revealed pituitary microadenomas in 3 patients but were normal in the others. Ectopic ACTH production was excluded in the 2 patients with normal MRI scans. All were given a therapeutic trial of cabergoline (1 mg daily). Four patients responded with a prompt fall in serum cortisol levels and had a sustained clinical and biochemical remission for 378, 44, 28 and 14 days, respectively. One patient failed to respond. In conclusion, we suggest that all patients with Cushing's disease should undergo a therapeutic trial of cabergoline. Responders can then be prepared for surgery or, if needed, treated medically in the long term.

KW - Adrenocorticotrophic hormone

KW - Cabergoline

KW - Case report

KW - Cushing's disease

KW - Dopamine receptors

KW - Oman

UR - http://www.scopus.com/inward/record.url?scp=84870677495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870677495&partnerID=8YFLogxK

U2 - 10.12816/0003176

DO - 10.12816/0003176

M3 - Article

C2 - 23275847

AN - SCOPUS:84870677495

SN - 2075-051X

VL - 12

SP - 493

EP - 497

JO - Sultan Qaboos University Medical Journal

JF - Sultan Qaboos University Medical Journal

IS - 4

ER -

Cushing's Disease: Sustained remission in five cases induced by medical therapy with the dopamine agonist cabergoline

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this